Jennifer M Kolb1, Kathryn Friedman Flack2, Prapti Chatterjee-Murphy3, Jay Desai4, Lars C Wallentin5, Michael Ezekowitz6, Stuart Connolly7, Paul Reilly8, Martina Brueckmann9,10, John Ilgenfritz11, James Aisenberg12. 1. Department of Gastroenterology and Hepatology, University of Colorado Hospital, Denver, CO, USA. 2. Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 6. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA. 7. Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. 8. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA. 9. Boehringer Ingelheim International GmbH, Ingelheim, Germany. 10. Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany. 11. Ilgenfritz Consulting LLC, Conshohocken, PA, USA. 12. Department of Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. j.aisenberg@nyga.md.
Abstract
BACKGROUND AND AIM: Different oral anticoagulants may be associated with gastrointestinal bleeding (GIB) from different locations or mucosal lesions. We aimed to test this hypothesis. METHODS: Two blinded gastroenterologists independently analyzed source documents from the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial of dabigatran 150 mg BID (D150), dabigatran 110 mg BID (D110) versus warfarin in non-valvular atrial fibrillation (NVAF). RESULTS:Major GIB events (total n = 546) andlife-threatening GIB events (n = 258) were more common with D150 versus warfarin (RR 1.57 [1.28-1.92] and RR 1.62 [1.20-2.18], respectively) and similar for D110 compared to warfarin (RR 1.11 [0.89-1.38] and RR 1.16 [0.84-1.61], respectively). Fatal bleeding was similarly rare across treatment groups. Lower GI major bleeding and life-threatening bleeding were more common with D150 compared to warfarin (RR 2.23 [1.47, 3.38] and RR 2.64 [1.36, 5.13], respectively) and with D110 compared to warfarin (RR 1.78 [1.16, 2.75] and RR 2.00 [1.00, 4.00], respectively). MGIB from colonic angiodysplasia was increased with dabigatran versus warfarin (P < 0.01 for both dose comparisons). Subacute and chronic MGIB events were more common with D150 than with warfarin (RR 1.72 [1.06, 2.78] and RR 1.66 [1.12, 2.45], respectively), as were hematochezia or melena (RR 1.67 [1.18, 2.36] and RR 1.72 [1.20, 2.47], respectively). CONCLUSIONS: In a chronic NVAF population, D150 but not D110 is associated with increased major and life-threatening GI bleeding in comparison with warfarin. At both dabigatran doses, increased bleeding from the colorectum, in particular from angiodysplasia, is seen.
RCT Entities:
BACKGROUND AND AIM: Different oral anticoagulants may be associated with gastrointestinal bleeding (GIB) from different locations or mucosal lesions. We aimed to test this hypothesis. METHODS: Two blinded gastroenterologists independently analyzed source documents from the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial of dabigatran 150 mg BID (D150), dabigatran 110 mg BID (D110) versus warfarin in non-valvular atrial fibrillation (NVAF). RESULTS: Major GIB events (total n = 546) and life-threatening GIB events (n = 258) were more common with D150 versus warfarin (RR 1.57 [1.28-1.92] and RR 1.62 [1.20-2.18], respectively) and similar for D110 compared to warfarin (RR 1.11 [0.89-1.38] and RR 1.16 [0.84-1.61], respectively). Fatal bleeding was similarly rare across treatment groups. Lower GI major bleeding and life-threatening bleeding were more common with D150 compared to warfarin (RR 2.23 [1.47, 3.38] and RR 2.64 [1.36, 5.13], respectively) and with D110 compared to warfarin (RR 1.78 [1.16, 2.75] and RR 2.00 [1.00, 4.00], respectively). MGIB from colonic angiodysplasia was increased with dabigatran versus warfarin (P < 0.01 for both dose comparisons). Subacute and chronic MGIB events were more common with D150 than with warfarin (RR 1.72 [1.06, 2.78] and RR 1.66 [1.12, 2.45], respectively), as were hematochezia or melena (RR 1.67 [1.18, 2.36] and RR 1.72 [1.20, 2.47], respectively). CONCLUSIONS: In a chronic NVAF population, D150 but not D110 is associated with increased major and life-threatening GI bleeding in comparison with warfarin. At both dabigatran doses, increased bleeding from the colorectum, in particular from angiodysplasia, is seen.
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin Journal: N Engl J Med Date: 2010-11-04 Impact factor: 91.245
Authors: John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf Journal: Circulation Date: 2011-05-16 Impact factor: 29.690
Authors: Esther W Chan; Wallis C Y Lau; Wai K Leung; Michael T C Mok; Ying He; Teresa S M Tong; Ian C K Wong Journal: Gastroenterology Date: 2015-05-08 Impact factor: 22.682
Authors: Kathryn F Flack; Jay Desai; Jennifer M Kolb; Prapti Chatterjee; Lars C Wallentin; Michael Ezekowitz; Salim Yusuf; Stuart Connolly; Paul Reilly; Martina Brueckmann; John Ilgenfritz; James Aisenberg Journal: Clin Gastroenterol Hepatol Date: 2016-10-17 Impact factor: 11.382
Authors: Matthew W Sherwood; James D Douketis; Manesh R Patel; Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Alex C Spyropoulos; Graeme J Hankey; Daniel E Singer; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Richard C Becker Journal: Circulation Date: 2014-02-19 Impact factor: 29.690
Authors: Elaine M Hylek; Claes Held; John H Alexander; Renato D Lopes; Raffaele De Caterina; Daniel M Wojdyla; Kurt Huber; Petr Jansky; Philippe Gabriel Steg; Michael Hanna; Laine Thomas; Lars Wallentin; Christopher B Granger Journal: J Am Coll Cardiol Date: 2014-03-19 Impact factor: 24.094
Authors: Stefan Blech; Thomas Ebner; Eva Ludwig-Schwellinger; Joachim Stangier; Willy Roth Journal: Drug Metab Dispos Date: 2007-11-15 Impact factor: 3.922
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245